Jiang Li, Li Xue, Cheng Qi, Zhang Bin-Hao
Department of Biliary and Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Street, Wuhan, 430030, China.
Department of Clinical Immunology, College of Laboratory Medicine, Tianjin Medical University, Tianjin, 300203, China.
Tumour Biol. 2015 Sep;36(9):7167-74. doi: 10.1007/s13277-015-3446-7. Epub 2015 Apr 17.
Our study aims to investigate the expression signature of plasma microRNA-106b (miRNA-106b, miR-106b) in hepatocellular carcinoma (HCC) patients and chronic liver disease (CLD) patients compared with healthy controls and further evaluate the potential clinical value of miR-106b as biomarker in HCC detection. In addition, a meta-analysis was conducted to assess the diagnostic performance of miR-106a/b as a biochemical marker for cancer screening. This study was divided into two phases. In the first phase, the expression levels of plasma miR-106b obtained from 108 subjects (47 HCC patients, 25 CLD patients, and 36 healthy controls) were measured by using qRT-PCR. Areas under receiver operating characteristic (ROC) curves (AUCs) were used to evaluate the diagnostic accuracy of plasma miR-106. In the second phase, a meta-analysis based on 11 previous researches as well as our current study was conducted to assess the potential clinical value of miR-106 in cancer detection. Plasma levels of miR-106b in HCC patients were significantly higher compared with CLD patients and healthy individuals. ROC curves suggested that plasma miR-106b yielded relative high sensitivities and specificities in differentiating HCC patients from CLD patients or healthy controls with corresponding AUC values of 0.726 and 0.879, respectively. In addition, miR-106b showed a relatively high accuracy in distinguishing CLD patients from healthy controls with its AUC value of 0.703. Furthermore, the meta-analysis for diagnostic performance of miR-106a/b showed a pooled sensitivity of 0.74, specificity of 0.75, and an AUC of 0.81. Subgroup analysis based on samples types revealed a higher diagnostic performance of miR-106 for cancer detection by using non-blood samples. Similarly, miR-106 as biomarker showed a higher diagnostic accuracy for gastric cancer detection. We found that plasma miR-106b has clinical value in the detection of HCC from healthy people and CLD patients. Further large-scale study may be needed to validate our findings.
我们的研究旨在调查与健康对照相比，肝细胞癌（HCC）患者和慢性肝病（CLD）患者血浆微小RNA-106b（miRNA-106b，miR-106b）的表达特征，并进一步评估miR-106b作为生物标志物在HCC检测中的潜在临床价值。此外，进行了一项荟萃分析，以评估miR-106a/b作为癌症筛查生化标志物的诊断性能。本研究分为两个阶段。在第一阶段，使用qRT-PCR测量了108名受试者（47名HCC患者、25名CLD患者和36名健康对照）血浆miR-106b的表达水平。采用受试者工作特征（ROC）曲线下面积（AUC）评估血浆miR-106的诊断准确性。在第二阶段，基于之前的11项研究以及我们目前的研究进行了一项荟萃分析，以评估miR-106在癌症检测中的潜在临床价值。与CLD患者和健康个体相比，HCC患者血浆miR-106b水平显著更高。ROC曲线表明，血浆miR-106b在区分HCC患者与CLD患者或健康对照方面具有相对较高的敏感性和特异性，相应的AUC值分别为0.726和0.879。此外，miR-106b在区分CLD患者与健康对照方面具有相对较高的准确性，其AUC值为0.703。此外，miR-106a/b诊断性能的荟萃分析显示合并敏感性为0.74，特异性为0.75，AUC为0.81。基于样本类型的亚组分析显示，使用非血液样本时，miR-106在癌症检测中的诊断性能更高。同样，miR-106作为生物标志物在胃癌检测中显示出更高的诊断准确性。我们发现血浆miR-106b在从健康人和CLD患者中检测HCC方面具有临床价值。可能需要进一步的大规模研究来验证我们的发现。
